Bioluminescence Ventures Emerges from Stealth, Secures $477M for Biotech Innovation

USA, San Francisco-based Bioluminescence Ventures has stepped out of stealth mode with an impressive $477 million in assets under management (AUM) spread across two funds. Founded and led by Managing Partner Kouki Harasaki, Ph.D., the biotech venture firm focuses on investing in companies translating groundbreaking science into next-generation medicines with a direct impact on patient outcomes. Bioluminescence Ventures is supported by institutional Limited Partners from the U.S. and around the world, and its portfolio already includes notable companies like Ensoma, Nido Biosciences, ReCode Therapeutics, and SURGE Therapeutics. The firm prioritizes leading investment rounds, collaborating closely with leadership teams to streamline diligence, negotiate fair terms, build syndicates, and swiftly finalize funding rounds.